|
- NCEP report - Medscape
The NCEP report also states that although the potential benefit of HDL-raising therapy has evoked considerable interest, "current documentation of risk reduction through controlled clinical trials
- The NCEP ATP III Guidelines: Friend or Foe? - Page 7 - Medscape
The new NCEP ATP III Cholesterol Guideline is an evidence-based guideline that supports more aggressive treatment with those at high-risk, such as those with atherosclerosis, diabetes mellitus
- Achieving National Cholesterol Education Program Goals
Abstract and Introduction National Cholesterol Education Program (NCEP) guidelines recommend low-density lipoprotein cholesterol (LDL-C) levels <100 mg dL for patients with coronary artery disease
- The NCEP ATP III Guidelines: Friend or Foe? - Page 2 - Medscape
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines provide an updated, evidence-based approach for screening and managing cholesterol in clinical
- NCEP-Defined Metabolic Syndrome, Diabetes Prevalence of CHD - Medscape
The frequent simultaneous presence of obesity, hyperlipidemia, diabetes, and hypertension was first described in the late 1960s
- EASE: Ezetimibe Add-on to Statin for Effectiveness Trial
Overall, more patients on statin plus ezetimibe reached their NCEP ATP III LDL-cholesterol goal than those on statin plus placebo (Table 2)
- Omega-3 Fatty Acids for the Treatment of Elevated Triglycerides
US NCEP ATP III Recommendations for Management of Hypertriglyceridemia In acknowledgement of the growing evidence supporting increased cardiovascular disease risks associated with elevated TG, the
- Meeting Lipid-Lowering Guidelines With Statin Treatment (Part I . . .
NCEP Guidelines in Clinical Practice The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) has recently updated its guidelines for cholesterol lowering to reduce CHD risk
|
|
|